Microscopic Polyangiitis Market 2022-2028: Analysed by Business Growth, Development Factors, Applications, and Future Prospects | Genentech, Inc., Celltrion, Inc., InflaRx N.V., ChemoCentryx Inc

Overview:

Microscopic polyangiitis (MPA) is a condition that causes small blood vessels to be inflamed. MPA can damage the blood vessels and cause problems in organs, such as the kidney, lungs, skin, nerves, and joints. Since MPA affects multiple organs, various symptoms such as fatigue, illness, loss of weight and appetite, fever, loss of sensation, and coughing blood can be seen or observed. MPA can be diagnosed with a blood test, urine test, and imaging techniques such as X-rays, magnetic resonance (MR), and computed tomography (CT). If results of these tests are positive, biopsy (tissue sample testing) is performed to confirm the presence of MPA.

Request PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/2529

Drivers:

Increasing demand for safe and effective treatment and frequent approvals by regulatory bodies such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and Medicines and Healthcare products Regulatory Agency (MHRA) are expected to augment the growth of the microscopic polyangiitis market. For instance, in October 2018, Genentech announced that the U.S. Food and Drug Administration (FDA) has approved an update to the Rituxan (rituximab) label to include information on follow up treatment of adult patients with Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA).

Moreover, players in the market are focusing on launching new treatment methods to meet increasing demand, which in turn is expected to propel the growth of the global microscopic polyangiitis market. For instance, in June 2018, InflaRx N.V. announced the approval of their Investigational New Drug (IND) application by the FDA. The open IND will allow InflaRx to start their planned phase II study to determine the safety and efficacy of IFX-1, a first-in-class anti-human complement factor C5a antibody, in patients with ANCA-associated vasculitis.

Market Taxonomy:

By Drug Type:

• Rituximab
• Azathioprine
• Cyclophosphamide
• Prednisone
• Pipeline drugs

By Route of Administration:

• Oral
• Injectable

By Distribution Channel:

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

By Region:

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East
• Africa

Restraints:

Risk of side effects is expected to hinder growth of the global microscopic polyangiitis market. Azathioprine involves side effects such as vision changes, seizure, joint pain, diarrhea, and loss of coordination. Corticosteroids also have side effects, such as intense pain and skin thinning.

Get PDF Sample Copy of Report (Including Full TOC, List of Tables & Figures, Chart) @ https://www.coherentmarketinsights.com/insight/request-sample/2529

Regional Analysis:

North America, Europe, and Asia Pacific are expected to witness robust growth in the global microscopic polyangiitis market due to the increasing number of clinical trials and introduction of novel treatment methods. For instance, Bristol-Myers Squibb, a pharma company, planned to conduct phase lll clinical trials for Abatacept (Orencia), which is expected to be completed by September 2022.

Moreover, in March 2018, Amerigen Pharmaceuticals Limited announced that its Abbreviated New Drug Application (ANDA) for cyclophosphamide capsules 25mg and 50mg has received final approval from the U.S. FDA.

Competitive landscape:

Major players active in the global microscopic polyangiitis market are Celltrion, Genentech, Inc., InflaRx N.V., Bristol-Myers Squibb Company, ChemoCentryx Inc., Teijin Pharma Ltd, TTY Biopharm Company, Sandoz International GmbH (Novartis Division), and Amerigen Pharmaceuticals Limited, among others.

Buy This Report with Flat USD 2000 Off @ https://www.coherentmarketinsights.com/promo/buynow/2529

Table of Content

Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Microscopic Polyangiitis Market Size Analysis from 2022 to 2028
11.6 COVID-19 Outbreak: Microscopic Polyangiitis Industry Impact

Chapter 2 Global Microscopic Polyangiitis Competition by Types, Applications, and Top Regions and Countries
2.1 Global Microscopic Polyangiitis (Volume and Value) by Type
2.3 Global Microscopic Polyangiitis (Volume and Value) by Regions

Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis

Chapter 4 Global Microscopic Polyangiitis Sales, Consumption, Export, Import by Regions (2017-2022)
Chapter 5 North America Microscopic Polyangiitis Market Analysis
Chapter 6 East Asia Microscopic Polyangiitis Market Analysis
Chapter 7 Europe Microscopic Polyangiitis Market Analysis
Chapter 8 South Asia Microscopic Polyangiitis Market Analysis
Chapter 9 Southeast Asia Microscopic Polyangiitis Market Analysis
Chapter 10 Middle East Microscopic Polyangiitis Market Analysis
Chapter 11 Africa Microscopic Polyangiitis Market Analysis
Chapter 12 Oceania Microscopic Polyangiitis Market Analysis
Chapter 13 South America Microscopic Polyangiitis Market Analysis
Chapter 14 Company Profiles and Key Figures in Microscopic Polyangiitis Business
Chapter 15 Global Microscopic Polyangiitis Market Forecast (2022-2028)
Chapter 16 Conclusions
Research Methodology